Saphenous Vein Graft Intervention

Saphenous vein graft percutaneous coronary intervention

In this issue of the Netherlands Heart Journal, IJsselmuiden et al. present a multicentre randomised control trial in which the STENTYS self-expanding bare metal stent (BMS) is compared with the STENTYS paclitaxel-eluting stent (PES) in saphenous vein grafts (SVGs). Primary endpoint of the trial was late lumen loss at six months follow-up, secondary endpoint was major adverse cardiac events (MA...

Percutaneous Coronary Intervention of Saphenous Vein Graft.

BACKGROUND Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been associated with a high risk of adverse ischemic events, but there is a paucity of contemporary data on the second-generation drug-eluting stent use within SVG, and the relative importance of high platelet reactivity (HPR) in SVG PCI versus native lesion PCI is unknown. We studied ischemic a...

Saphenous vein graft intervention discussion on acute vein graft occlusion intervention.

We read with interest the State-of-the-Art paper on saphenous vein graft (SVG) intervention by Lee et al. (1), and commend the authors for a comprehensive review. We would like to highlight that the review failed to mention the management of ST-segment elevation myocardial infarction due to acute SVG occlusion. Retrospective data (2,3) have confirmed his area remains a particularly high-risk su...

Saphenous Vein Graft Aneurysms

Embolic Protection Devices in Aortocoronary Saphenous Vein Graft Intervention

E mbolic protection devices (EPDs) were first developed to provide cerebral protection during carotid artery stenting and have led to marked reductions in the combined endpoints of stroke or death.1,2 Therefore, it was natural that these devices should be applied to native coronary and aortocoronary saphenous vein graft (SVG) interventions to reduce clinically significant atheroand thromboembol...